In KRAS-mutant colorectal cancer (CRC), KRAS∗-mediated repression of interferon regulatory factor 2 (IRF2) that directly represses CXCL3 expression results in high expression of CXCL3, which binds to CXCR2 on MDSCs and promotes their migration to the TME. This evidence concerns the gene CXCL3 and colorectal carcinoma.